Compare PECO & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PECO | DYN |
|---|---|---|
| Founded | 1991 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.8B |
| IPO Year | 2010 | 2020 |
| Metric | PECO | DYN |
|---|---|---|
| Price | $39.12 | $25.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | ★ $39.71 | $37.00 |
| AVG Volume (30 Days) | 710.3K | ★ 1.7M |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | ★ 74.51 | N/A |
| EPS | ★ 0.56 | N/A |
| Revenue | ★ $726,594,000.00 | N/A |
| Revenue This Year | $5.82 | N/A |
| Revenue Next Year | $3.81 | N/A |
| P/E Ratio | $69.50 | ★ N/A |
| Revenue Growth | ★ 9.86 | N/A |
| 52 Week Low | $32.98 | $11.92 |
| 52 Week High | $44.38 | $27.31 |
| Indicator | PECO | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 37.47 | 48.84 |
| Support Level | $38.99 | $16.45 |
| Resistance Level | $39.86 | $26.96 |
| Average True Range (ATR) | 0.52 | 0.88 |
| MACD | -0.03 | -0.26 |
| Stochastic Oscillator | 26.14 | 30.08 |
Phillips Edison & Co Inc is a real estate investment trust. The company also operates a third-party investment management business providing property management and advisory services to four unconsolidated institutional joint ventures, in which it has a partial ownership interest, and one private fund. It invests in well-occupied, grocery-anchored neighborhood and community shopping centers. It holds an integrated in-house operating platform built on a market of expertise designed to optimize property value and consistently deliver a great shopping experience.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.